August 2009 Volume 6 Number 8
Visit Nature Reviews Clinical Oncology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=40&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Clinical Oncology online. To purchase a subscription,
please visit:
http://links.ealert.nature.com/ctt?kn=45&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=61&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
*********************************************************************
Nature Reviews Clinical Oncology Impact Factor: 9.113*
(*Journal Citation Reports, Thomson, 2005)
*********************************************************************
=========================== ADVERTISEMENT ===========================
AACR Conference:
Genetics and Biology of Brain Cancers - Dec. 13-15, 2009, in San Diego, CA
Lynda Chin, Webster K. Cavenee, Paul S. Mischel, and
Mitchel S. Berger, Chairpersons
This conference will invite discussion on developments in targeted
therapies based on a mechanistic understanding of the molecular
circuitry of brain cancer.
Abstract Deadline: October 5, 2009
=====================================================================
=========================== ADVERTISEMENT ===========================
Nature Reviews Clinical Oncology brings all the qualities of the
top-ranked life sciences series to the clinical sciences and is a
valuable resource for practicing physicians and clinical academics.
Visit Nature Reviews Clinical Oncology online at
http://links.ealert.nature.com/ctt?kn=37&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
and keep up-to-date with the latest advances in oncology.
=====================================================================
----------------------
RESEARCH HIGHLIGHTS
----------------------
Imaging: MRI and molecular profiles: improving prediction
p435 | doi:10.1038/nrclinonc.2009.95
http://links.ealert.nature.com/ctt?kn=69&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Survivin: Surviving gastric cancer
p436 | doi:10.1038/nrclinonc.2009.96
http://links.ealert.nature.com/ctt?kn=48&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Radiotherapy: Five-year PSA value predicts survival
p436 | doi:10.1038/nrclinonc.2009.99
http://links.ealert.nature.com/ctt?kn=80&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Chemotherapy: Paclitaxel adjuvant therapy improves relapse-free survival
p437 | doi:10.1038/nrclinonc.2009.100
http://links.ealert.nature.com/ctt?kn=32&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Medical oncology: CEA levels predict response to therapy in rectal cancer
p437 | doi:10.1038/nrclinonc.2009.97
http://links.ealert.nature.com/ctt?kn=60&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Medical oncology: Long-term androgen suppression improves survival
p438 | doi:10.1038/nrclinonc.2009.101
http://links.ealert.nature.com/ctt?kn=43&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Imaging: Radiation response does not correlate with PET-CT
p438 | doi:10.1038/nrclinonc.2009.98
http://links.ealert.nature.com/ctt?kn=73&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Surgery: Are we performing enough tonsillectomies?
John Phillips and Andreas Hilger
p439 | doi:10.1038/nrclinonc.2009.105
The incidence of tonsillar cancer in the UK has doubled over the past
decade and the discovery of the human papillomavirus in tonsillar cancer
specimens has been hypothesized to be the cause. We discuss and propose
an explanation of how a reduction in tonsillectomy rates may be responsible
for this increase in tonsillar cancer.
http://links.ealert.nature.com/ctt?kn=28&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Pediatric oncology: Methotrexate-exploring dosing and administration
in ALCL
John T. Sandlund and Joseph H. Laver
p440 | doi:10.1038/nrclinonc.2009.107
Central nervous system prophylaxis is recommended with the administration
of high-dose methotrexate and/or intrathecal injection of chemotherapy
in patients with anaplastic large-cell lymphoma (ALCL). Researchers
investigated whether methotrexate dose, infusion duration and intrathecal
mode of administration had an impact on the risk of systemic and central
nervous system relapses in children with ALCL.
http://links.ealert.nature.com/ctt?kn=3&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Targeted therapies: GIST adjuvant therapy-some answers and more questions
Burton Eisenberg
p441 | doi:10.1038/nrclinonc.2009.104
Imatinib is known to be effective in the first-line treatment of metastatic
gastrointestinal stromal tumors. A randomized, placebo-controlled trial
has now shown that imatinib is safe and improves recurrence-free survival
when used as adjuvant therapy after surgical resection of a primary
gastrointestinal stromal tumor.
http://links.ealert.nature.com/ctt?kn=77&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Radiotherapy: Prophylactic cranial irradiation for small-cell lung cancer
Martin Stuschke and Christoph Pottgen
p443 | doi:10.1038/nrclinonc.2009.103
Patients with extensive small-cell lung cancer who are treated with
prophylactic cranial irradiation experience fewer brain metastases and
prolonged survival compared with their counterparts. Slotman and colleagues
have presented a detailed analysis of the effects of prophylactic cranial
irradiation on health-related quality of life in these patients.
http://links.ealert.nature.com/ctt?kn=23&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Quantitative imaging biomarkers in neuro-oncology
Adam D. Waldman, Alan Jackson, Stephen J. Price, Christopher A. Clark,
Thomas C. Booth, Dorothee P. Auer, Paul S. Tofts, David J. Collins,
Martin O. Leach & Jeremy H. Rees (on behalf of the National Cancer
Research Institute Brain Tumour Imaging Subgroup)
Published online: 23 June 2009
p445 | doi:10.1038/nrclinonc.2009.92
Conventional structural imaging provides limited information on tumor
characterization and prognosis. Advances in neurosurgical techniques,
radiotherapy planning and novel drug treatments for brain tumors have
generated increasing need for reproducible, non-invasive, quantitative,
imaging biomarkers. This Review discusses the role of physiological MRI
and PET molecular imaging in understanding metabolic processes associated
with tumor growth, blood flow and ultrastructure.
Abstract: http://links.ealert.nature.com/ctt?kn=46&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=8&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Systems pathology-taking molecular pathology into a new dimension
Dana Faratian, Robert G. Clyde, John W. Crawford and David J. Harrison
Published online: 07 July 2009
p455 | doi:10.1038/nrclinonc.2009.102
Dynamics of cells reactions and behavior between cells can be integrated
into models of cancer using systems pathology. Integrating multiple data
from the clinic to make models sufficiently robust to be of practical use
is a challenge. The difficulties in using mathematics to model cancer are
highlighted, and some approaches in systems biology and experimental
pathology that may be applied successfully in the clinic are discussed.
Abstract: http://links.ealert.nature.com/ctt?kn=41&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=66&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Article series: Antiangiogenic Clinical Strategies
Adverse effects of anticancer agents that target the VEGF pathway
Helen X. Chen and Jessica N. Cleck
Published online: 07 July 2009
p465 | doi:10.1038/nrclinonc.2009.94
Antiangiogenic agents that target the VEGF pathway have become an
important part of standard therapy in multiple cancer indications.
Although most adverse effects of VEGF inhibitors are modest and
manageable, some are associated with serious and life-threatening
consequences. This Review examines the toxicity profiles of anti-VEGF
monoclonal antibodies and small-molecule inhibitors and considers the
potential mechanisms of the adverse effects, risk factors, and the
implications for patient management.
Abstract: http://links.ealert.nature.com/ctt?kn=35&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=10&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Immunotherapeutic strategies in kidney cancer-when TKIs are not enough
Swethajit Biswas and Tim Eisen
Published online: 23 June 2009
p478 | doi:10.1038/nrclinonc.2009.91
The management of metastatic clear-cell renal-cell carcinoma has been
revolutionized by the approval of targeted therapies. These targeted
therapies have, however, been unable to provide robust complete responses
in metastatic clear-cell renal-cell carcinoma. The authors of this Review
discuss the role of immunotherapeutic approaches in the management of this
disease.
Abstract: http://links.ealert.nature.com/ctt?kn=75&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=57&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
----------------------
CASE STUDY
----------------------
Eleven years disease-free: role of chemotherapy in metastatic BRCA2-related
breast cancer
Fleur Huang, Yael B. Kushner, Adrian Langleben and William D. Foulkes
p488 | doi:10.1038/nrclinonc.2009.90
Lasting complete remission from widespread bone metastases is rare. The
case of a 41-year-old premenopausal woman diagnosed with right-sided
infiltrating ductal breast carcinoma and BRCA2 mutation is described.
She received high-dose anthracycline-based induction chemotherapy followed
by autologous bone marrow transplantation with high-dose alkylator and
platin-based conditioning regimens. The authors comment on the reasons
for this unusual and sustained complete remission from widely metastatic
breast cancer and the patient-specific factors that may have contributed
to this outcome.
Abstract: http://links.ealert.nature.com/ctt?kn=19&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=7&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Visit the Nature Reviews Clinical Oncology website:
- Advanced online publication
- Search across related content from nature.com
- Web feeds (RSS)
- Downloadable PowerPoint slides of figures and supplementary information
- Links to the European School of Oncology, including e-grandrounds
http://links.ealert.nature.com/ctt?kn=37&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=31&m=33785413&r=MTc2NDg2OTc4MQS2&b=2&j=NTQ3MzA5NTUS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2009 Nature Publishing Group
=====================================================================
